Business Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc
ISIN : CNE100006624
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 5.25 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.27 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | 7.43 | |||||
Beneish M-Score | -2.74 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Future 3-5Y EPS without NRI Growth Rate Estimate | -15.58 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 29.38 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.11 | |||||
9-Day RSI | 44.85 | |||||
14-Day RSI | 43.67 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 4.86 | |||||
Quick Ratio | 4.86 | |||||
Cash Ratio | 4.28 | |||||
Days Sales Outstanding | 28.54 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | -2.95 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -94519.43 | |||||
Net Margin % | -98351.9 | |||||
FCF Margin % | -95222 | |||||
ROE % | -57.23 | |||||
ROA % | -48.71 | |||||
ROIC % | -137.02 | |||||
ROC (Joel Greenblatt) % | -282.63 | |||||
ROCE % | -55.87 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5670 | |||||
PB Ratio | 3.28 | |||||
Price-to-Tangible-Book | 3.2 | |||||
EV-to-EBIT | -4.05 | |||||
EV-to-EBITDA | -4.3 | |||||
EV-to-Revenue | 3966.25 | |||||
EV-to-FCF | -4.12 | |||||
Price-to-Net-Current-Asset-Value | 4.57 | |||||
Price-to-Net-Cash | 5.33 | |||||
Earnings Yield (Greenblatt) % | -24.67 | |||||
FCF Yield % | -19.03 |